Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RA-BEYOND: Baricitinib Long-Term Extension in RA
NCT01885078Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2013
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 38
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in rheumatoid arthritis (RA) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants Who Experienced Adverse Events (AEs) or Serious AE. Started Jun 2013; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01885078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01885078.